Robotic surgery is no longer just a story about high-end operating theatres and billion-dollar flagship systems.
A fresh wave of clinical studies, regulatory milestones and specialist devices is pushing healthcare robotics into new corners of medicine — from gastrointestinal procedures and orthopaedics to micro-scale robotics and AI-assisted navigation systems.
Two studies released this week highlighted how quickly that shift is accelerating in gastrointestinal care, an area increasingly viewed as a major growth frontier for medical robotics.
US-based Neptune Medical reported successful results from a 50-patient first-in-human study of its Triton robotic endoscopy system, with the company achieving 100% cecal intubation during colonoscopy procedures and reporting no device-related adverse events.
At the same time, Johnson & Johnson (NYSE:JNJ) released pivotal study results for its long-awaited Ottava soft tissue surgical robot, with all gastric bypass procedures in the study completed robotically without the need to convert to laparoscopic or open surgery.
While the announcements were very different in scale, both point to the same broader industry trend: robotics is expanding beyond traditional laparoscopic surgery into more specialised, high-volume and procedure-specific applications.
GI robotics moves into focus
Gastrointestinal procedures are increasingly being viewed as one of the next major frontiers for healthcare robotics.
Colonoscopies alone are performed millions of times each year globally, while demand continues to rise alongside ageing populations and expanding cancer screening programs.
For developers, the attraction is obvious. GI procedures combine high patient volumes with persistent challenges around operator fatigue, workflow efficiency and procedural consistency — exactly the kinds of problems robotics and automation are designed to address.
The Neptune study reflects a growing push towards robotic endoscopy systems that aim to reduce the physical demands of colonoscopy while improving navigation and patient comfort. Developers across the sector are also exploring softer robotic systems, self-propelled devices and AI-assisted lesion detection tools.
Competition spreads beyond da Vinci
The GI push is only one part of a much larger shift taking place across healthcare robotics.
For years, Intuitive Surgical Inc (NASDAQ:ISRG, XETRA:IUI1)’s da Vinci system dominated robotic surgery with relatively limited large-scale competition. That landscape is now changing rapidly.
Johnson & Johnson’s Ottava program is one of several major platforms attempting to challenge that dominance, alongside Medtronic PLC (NYSE:MDT, XETRA:2M6)’s Hugo robotic-assisted surgery system and systems from companies including CMR Surgical, Moon Surgical and Distalmotion.
Importantly, many of the newer entrants are taking a different approach from earlier generations of surgical robots.
Rather than building massive, highly specialised systems aimed only at elite hospitals, many developers are focusing on smaller, more modular and potentially lower-cost platforms designed for broader clinical adoption.
That trend is becoming increasingly visible outside traditional surgery settings as well.
Earlier this year, Stryker Corp (NYSE:SYK) began first clinical cases using its handheld orthopedic robotic platform, reflecting growing demand for more flexible systems in musculoskeletal procedures. At the same time, research groups and startups are pushing further into miniature and micro-scale robotics capable of navigating inside the body with increasing precision.
AI becomes part of the robotics equation
The next phase of healthcare robotics is also becoming closely tied to advances in artificial intelligence.
Modern systems are increasingly combining robotics with real-time imaging, computer vision, navigation software and AI-assisted decision-making tools. In many cases, the value proposition is shifting from pure mechanical automation towards integrated procedural guidance and workflow optimisation.
That convergence is beginning to reshape investor expectations around the sector.
According to recent market forecasts, the minimally invasive medical robotics market is expected to continue expanding strongly over the next decade as hospitals pursue shorter recovery times, lower complication rates and more efficient operating workflows.
Still, the commercial hurdles remain substantial.
Robotic systems are expensive to develop, clinical validation can take years and hospitals remain cautious about large capital spending commitments. Regulatory scrutiny is also increasing as AI becomes more deeply integrated into clinical systems.
From flagship systems to everyday care
Even so, the pace of development is clearly accelerating.
This week’s GI-focused studies may look incremental on their own. But taken alongside the broader wave of new robotic systems, specialised applications and AI-enabled surgical platforms emerging across healthcare, they point to a sector moving well beyond its first generation.
The next battle in healthcare robotics may no longer be about who builds the biggest surgical robot. Increasingly, it is about who can build systems that are smaller, smarter, more specialised — and scalable across everyday clinical care.